Compare Boston Scientific Corporation (BSX) vs Stryker Corporation (SYK) Price & Performance

Boston Scientific (BSX) trades at $51.66, up 2.38% today, showing strong momentum with three consecutive quarterly earnings beats. The stock maintains bullish technical signals with moving averages supporting upward movement, though oscillators indicate potential overbought conditions. Fundamentally, BSX demonstrates robust growth with 2025 revenue reaching $20.07B and net income margin expanding to 14.43%, supported by strong cash flow generation of $1.54B in 2025.

The outlook remains positive with 86% analyst buy ratings and a $67.21 consensus price target offering 30% upside potential. Key risks include competitive pressures in WATCHMAN and electrophysiology segments, along with recent guidance cuts. Insider buying by the CEO and director signals management confidence in the company's long-term prospects despite near-term challenges.

Stryker (SYK) trades at $345.86, up slightly by 0.01% today, with a bullish technical signal and strong analyst support. The company reported a Q2 2026 earnings beat with $3.69 EPS versus $3.49 expected, driven by 9% organic sales growth and recovery from a cyber incident. Fundamentals show robust profitability with a 14.43% net income margin and 16.51% ROE, though valuation ratios like a P/E of 36.08 are elevated.

Outlook remains positive with raised guidance and new product launches like Mako RPS expanding market reach. Key risks include execution challenges post-cyberattack and competitive pressures. The consensus price target of $379.44 implies ~10% upside, supported by 74% buy ratings from analysts.